FOLFIRI方案治疗晚期胃癌的临床研究  

Clinical Study of FOLFIRI Regimen in Treatment of Advanced Gastric Cancer

作　　者：高宏丽[1] 孙景香[1] 史鑫[1] 庞蔚[1] 周爱华[1] 

机构地区：[1]济南市第四人民医院,济南250031

出　　处：《中国医疗前沿》2009年第11期7-8,共2页China Healthcare Innovation

摘　　要：目的评价FOLFIRI方案治疗晚期胃癌的临床疗效和毒副反应。方法对36例晚期胃癌患者,采用FOLFIRI方案治疗。FOLFIRI方案:伊利替康150mg/m2持续静脉滴入30～90分钟,d1;甲酰四氢叶酸200mg/m2持续静脉滴入2h,d1、2;5-氟尿嘧啶400mg/m2静脉推注,d1、2;600mg/m2静脉微量泵44h持续滴入,14天为1个周期,每连用4个周期评价一次疗效。结果36例患者均可评价疗效和毒副反应,获得CR2例,占5.6%,PR11例,占30.6%,SD13例,占36.1%,PD11例,占30.6%,有效率为36.1%(13/36),中位肿瘤进展时间为4.5个月,中位生存期为9.3个月。毒副反应主要为骨髓抑制、迟发性腹泻。结论对于晚期胃癌患者,FOLFIRI方案是一种有效的、不良反应可以耐受的治疗手段,值得进一步研究。Objective To evaluate the efficacy and toxicity of FOLFIRI regimen in the treatment of advanced gastric cancer. Method Thirty-six cases received FOLFIRI. FOLFIRI regimen： CPT- Ⅱ 150mg/m^2 iv drip 30-90 minutes, d1, CF 200mg/m^2 iv drip 2 hours all, 2, followed by 5-Fu 400 mg/m^2 iv d1,2, 600 mg/m^2 using an ambulatory pump continuous infusion for 44 hours, and 14 days as an cycle. The efficacy was evaluated after every 4 cycles. Results All the 36 cases were available for objective response. 2 patients achieved complete response（CR）, 11 patients partial response（PR）, 13 patients stable disease（SD）, and 11 patients progression disease（PD）. The overall response rate was 36.1%. The median time to progression and overall survival was 4.5 and 9. 3 months. The main toxicities were myelosuppression and tardive diarrhea. Conclusion FOLFIRI regimen is effective and well tolerable in the treatment of advanced gastric cancer, and is worth to be used and researched widely.

关 键 词：FOLFIRI方案 晚期胃癌 化学治疗 

分 类 号：R735.2[医药卫生—肿瘤]